[1] CHEN G, KANG W, LI W, et al. Oral delivery of protein and peptide drugs: from non-specific formulation approaches to intestinal cell targeting strategies [J]. Theranostics, 2022, 12(3): 1419-1439.
[2] PARK K, KWON I C, PARK K. Oral protein delivery: current status and future prospect [J]. React Funct Polym, 2011, 71(3): 280-287.
[3] LUNDQUIST P , ARTURSSON P . Oral absorption of peptides and nanoparticles across the human intestine: opportunities, limitations and studies in human tissues [J]. Adv Drug Deliv Rev, 2016, 106(Part B): 256-276.
[4] TONG T, W ANG L, YOU X, et al. Nano and microscale delivery platforms for enhanced oral peptide/protein bioavailability [J]. Biomater Sci, 2020, 8(21): 5804-5823.
[5] SILV A A C, SANTOS D, FERREIRA D, et al. Lipid-based nanocarriers as an alternative for oral delivery of poorly water- soluble drugs: peroral and mucosal routes [J]. Curr Med Chem, 2012, 19(26): 4495-4510.
[6] SARMENTO B, MAZZAGLIA D, BONFERONI M C, et al. Effect of chitosan coating in overcoming the phagocytosis of insulin loaded solid lipid nanoparticles by mononuclear phagocyte system [J]. Carbohyd Polymers, 2011, 84(3): 919-925.
[7] HADDADZADEGAN S, DORKOOSH F, BERNKOP-SCHNÜRCH A. Oral delivery of therapeutic peptides and proteins: technology landscape of lipid-based
nanocarriers [J]. Adv Drug Deliv Rev, 2022, 182: 114097.
[8] SHAN W, ZHU X, LIU M, et al. Overcoming the diffusion barrier of mucus and
absorption barrier of epithelium by self-assembled nanoparticles for oral delivery of insulin [J]. ACS Nano, 2015, 9(3): 2345-2356.
[9] ZUPANČIČ O, BERNKOP-SCHNÜRCH A. Lipophilic peptide character - what
oral barriers fear the most [J]. J Control Release, 2017, 255: 242-257.
[10] RISTROPH K D, PRUD'HOMME R K. Hydrophobic ion pairing: encapsulating small molecules, peptides, and proteins into nanocarriers [J]. Nanoscale Adv, 2019, 1(11): 4207-4237.
[11] MUNTONI E, MARINI E, AHMADI N, et al. Lipid nanoparticles as vehicles for oral delivery of insulin and insulin analogs: preliminary ex vivo and in vivo studies [J]. Acta Diabetol, 2019, 56(12): 1283-1292.
[12] SMART A L, GAISFORD S, BASIT A W. Oral peptide and protein delivery: intestinal obstacles and commercial prospects [J]. Expert Opin Drug Deliv, 2014, 11(8): 1323-1335.
[13] ARNOLD Y E, IMANIDIS G, KUENTZ M. In vitro digestion kinetics of
excipients for lipid-based drug delivery and introduction of a relative lipolysis half life [J]. Drug Dev Ind Pharm, 2012, 38(10): 1262-1269.
[14] DAMGÉ C, REIS C P , MAINCENT P . Nanoparticle strategies for the oral delivery
of insulin [J]. Expert Opin Drug Deliv, 2008, 5(1): 45-68.
[15] BA TTAGLIA L, GALLARA TE M. Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery [J]. Expert Opin Drug Deliv, 2012, 9(5): 497-508.
[16] DAS S, CHAUDHURY A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery [J]. AAPS PharmSciTech, 2011, 12(1): 62-76.
[17] MEANEY C M, O'DRISCOLL C M. A comparison of the permeation
enhancement potential of simple bile salt and mixed bile salt: fatty acid micellar systems using the CaCo-2 cell culture model [J]. Int J Pharm, 2000, 207(1/2): 21-30.
[18] ZHANG Z, GAO F, JIANG S, et al. Bile salts enhance the intestinal absorption of lipophilic drug loaded lipid nanocarriers: mechanism and effect in rats [J]. Int J Pharm, 2013, 452(1/2): 374-381.
[19] MCCLEMENTS D J. Encapsulation, protection, and delivery of bioactive proteins and peptides using nanoparticle and microparticle systems: a review [J]. Adv Colloid Interface Sci, 2018, 253: 1-22.
[20] MUCHOW M, MAINCENT P , MULLER R H. Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery [J]. Drug Dev Ind Pharm, 2008, 34(12): 1394-1405.
[21] SAINI A, PANW AR D, PANESAR P S, et al. Encapsulation of functional ingredients in lipidic nanocarriers and antimicrobial applications: a review [J]. Environ Chem Lett, 2021, 19: 1107-1134.
[22] BANERJEE S, PILLAI J. Solid lipid matrix mediated nanoarchitectonics for improved oral bioavailability of drugs [J]. Expert Opin Drug Metab Toxicol, 2019, 15(6): 499-515.
技术资料
